Syn­cona takes write-down on Swan­Bio as biotech halves work­force to fo­cus on one gene ther­a­py

UK life sci­ences in­vestor Syn­cona has tak­en a write-down on its in­vest­ment in pri­vate gene ther­a­py biotech Swan­Bio, part of a broad­er hit to its port­fo­lio, as the val­ue of its pub­licly list­ed life sci­ences hold­ings has de­clined.

Swan­Bio is lay­ing off about half of its em­ploy­ees, a spokesper­son for the com­pa­ny told End­points News via email Thurs­day morn­ing.

“Macro con­di­tions” and “com­pa­ny spe­cif­ic chal­lenges” have led to a £77.9 mil­lion (about $90 mil­lion) drop in the val­u­a­tions of Syn­cona’s pub­licly-list­ed port­fo­lio com­pa­nies, which in­clude Au­to­lus and Free­line Ther­a­peu­tics. The Swan­Bio val­ue near­ly halved, down £51.0 mil­lion, or rough­ly $65 mil­lion, Syn­cona said in its an­nu­al fi­nan­cial per­for­mance up­date on Thurs­day, for the 12-month stretch that end­ed March 31.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER